Publications by authors named "Johannes Drach"

66Publications

Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience.

Oncology 2017 12;93(5):295-301. Epub 2017 Aug 12.

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/478265
Publisher Site
http://dx.doi.org/10.1159/000478265DOI Listing
March 2018

Novel agents have a significant impact on survival of patients with multiple myeloma.

Wien Klin Wochenschr 2015 Feb 22;127(3-4):92-7. Epub 2015 Jan 22.

Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-014-0605-6DOI Listing
February 2015

Extracellular matrix remodeling by bone marrow fibroblast-like cells correlates with disease progression in multiple myeloma.

J Proteome Res 2014 Feb 2;13(2):844-54. Epub 2013 Dec 2.

Faculty of Chemistry, Institute of Analytical Chemistry, University of Vienna , Währingerstraße 38, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/pr400881p
Publisher Site
http://dx.doi.org/10.1021/pr400881pDOI Listing
February 2014

Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma.

Eur J Cancer 2014 Feb 15;50(3):622-7. Epub 2013 Nov 15.

Children's Cancer Research Institute, Vienna, Austria; Department of Pediatrics, Medical University Vienna, Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.10.013DOI Listing
February 2014

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

J Clin Oncol 2013 Oct 3;31(29):3688-95. Epub 2013 Sep 3.

Andre Goy, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack; Lei Zhang, Sherri Cicero, and Tommy Fu, Celgene, Summit, NJ; Rajni Sinha, Emory University Winship Cancer Institute, Atlanta, GA; Michael E. Williams, University of Virginia Health System, Charlottesville, VA; Sevgi Kalayoglu Besisik, Istanbul University Faculty of Medicine, Istanbul, Turkey; Johannes Drach, Medical University of Vienna, Vienna, Austria; Radhakrishnan Ramchandren, Karmanos Cancer Institute, Detroit, MI; and Thomas E. Witzig, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.2835DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879693PMC
October 2013

Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma.

J Cancer Res Clin Oncol 2013 Oct 20;139(10):1771-5. Epub 2013 Jul 20.

Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-013-1475-4DOI Listing
October 2013

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.

Br J Haematol 2013 Mar 7;160(5):649-59. Epub 2013 Jan 7.

Department of Cellular Biotechnology and Haematology, Sapienza University of Rome, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.12198DOI Listing
March 2013

Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws.

Head Neck 2012 Feb 11;34(2):194-200. Epub 2011 Mar 11.

University Clinic of Craniofacial, Maxillofacial and Oral Surgery, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hed.21708
Publisher Site
http://dx.doi.org/10.1002/hed.21708DOI Listing
February 2012

Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.

Transplantation 2010 Jun;89(11):1385-90

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0b013e3181d9e1c0DOI Listing
June 2010

Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.

Ann Hematol 2010 Mar 20;89(3):273-82. Epub 2009 Aug 20.

Department Internal Medicine 3, Centre for Hematology and Medical Oncology, General Hospital Linz, Krankenhausstrasse 9, 4020, Linz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-009-0811-xDOI Listing
March 2010

Proteome maps of the main human peripheral blood constituents.

J Proteome Res 2009 Aug;8(8):3834-43

Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/pr801085gDOI Listing
August 2009

Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.

Clin Transpl 2009 :415-20

Division of Nephrology and Dialysis, Department of Medicine II, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
July 2010

Lenalidomide: a new therapy for multiple myeloma.

Cancer Treat Rev 2008 May 29;34(3):283-91. Epub 2008 Jan 29.

Department of Hematology, University of Torino, Ospedale Molinette, Via Genova 3, 10126 Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2007.12.005DOI Listing
May 2008

Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.

Cancer Res 2008 Jan;68(1):44-54

Division of Oncology, Department of Medicine I, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-07-2531DOI Listing
January 2008

Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.

Haematologica 2007 Oct;92(10):1411-4

Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1170 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.11463DOI Listing
October 2007

The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.

Oncologist 2007 Mar;12(3):281-90

Institut Gustave-Roussy, Dept. of Medicine, 39 Rue Camille-Desmoulins, Villejuif Cedex 94805, France.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.12-3-281DOI Listing
March 2007

Further insights into multiple myeloma genetics.

Authors:
Johannes Drach

Haematologica 2006 Feb;91(2):147a

Medical University Vienna, Dept. of Medicine I, Clinical Division of Oncology Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
February 2006

Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.

Oncology 2005 16;69(6):499-502. Epub 2006 Jan 16.

Division of Bone Marrow Transplantation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/91031
Publisher Site
http://dx.doi.org/10.1159/000091031DOI Listing
March 2006

Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy.

Scand J Gastroenterol 2005 Oct;40(10):1222-5

Department of Medicine I, Medical University Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365520510023440DOI Listing
October 2005

Treatment of mantle cell lymphoma: targeting the microenvironment.

Expert Rev Anticancer Ther 2005 Jun;5(3):477-85

Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer, Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737140.5.3.477DOI Listing
June 2005

Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.

Leuk Res 2005 Dec 16;29(12):1473-7. Epub 2005 Jun 16.

Department of Internal Medicine I, Clinical Division of Oncology, Bone marrow transplantation and Hematology & Hemostaseology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2005.05.003DOI Listing
December 2005

Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.

Onkologie 2005 Feb;28(2):73-8

Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000083223DOI Listing
February 2005

Effective treatment of primary plasma cell leukemia with thalidomide and dexamethasone - a case report.

Hematol J 2004 ;5(4):361-3

Clinical Division of Oncology, Department of Medicine 1, University Hospital Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200375DOI Listing
February 2005

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.

Blood 2004 Oct 27;104(8):2269-71. Epub 2004 May 27.

University Hospital Vienna, Department of Medicine I, Clinical Division of Oncology, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-03-10
Publisher Site
http://dx.doi.org/10.1182/blood-2004-03-1091DOI Listing
October 2004

Concomitant occurrence of MALT lymphoma and multiple myeloma.

Ann Hematol 2004 Sep 9;83(9):600-3. Epub 2004 Apr 9.

Clinical Division of Oncology, Department of Medicine I, University Hospital Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-004-0870-yDOI Listing
September 2004

Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.

Oncology 2003 ;65(4):306-10

Department of Internal Medicine I, Division of Oncology and Internal Medicine IV, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/74641
Publisher Site
http://dx.doi.org/10.1159/000074641DOI Listing
February 2004

New insights into the pathophysiology of multiple myeloma.

Lancet Oncol 2003 Sep;4(9):557-64

Department of Medicine, Clinical Division of Oncology, University Hospital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1470-2045(03)01195-1DOI Listing
September 2003

Paraneoplastic pemphigus in association with hepatocellular carcinoma.

J Am Acad Dermatol 2003 Sep;49(3):538-40

Department of Dermatology, School of Medicine, University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1067/s0190-9622(03)01581-0DOI Listing
September 2003

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.

Eur J Haematol 2003 Sep;71(3):179-83

Department of Medicine I, Clinical Division of Oncology and Division of Hematology, University Hospital Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-0609.2003.00111.xDOI Listing
September 2003

Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.

Clin Cancer Res 2003 Feb;9(2):820-6

Department of Medicine I, Clinical Division of Oncology, University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
February 2003

Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis.

Dig Dis Sci 2002 Sep;47(9):1909-14

Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie, University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1019623418063DOI Listing
September 2002

Chromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19+ cells in patients with myeloma and monoclonal gammopathy of undetermined significance.

Br J Haematol 2002 Jun;117(4):852-9

First Department of Internal Medicine and Medical Oncology, Wilhelminenspital, University of Vienna, Montleartstrasse 37, 1160 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2141.2002.03529.xDOI Listing
June 2002

Idiopathic eosinophilic endomyocarditis in the absence of peripheral eosinophilia.

Leuk Lymphoma 2002 Jan;43(1):215-8

Department of Cardiology, University of Vienna Medical School, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190210184DOI Listing
January 2002